Loss of the initial efficacy of levetiracetam in patients with refractory epilepsy  by Lee, Gha-hyun et al.
Seizure 22 (2013) 185–188Loss of the initial efﬁcacy of levetiracetam in patients with refractory epilepsy
Gha-hyun Lee, Bo-mi Kim, Joong Koo Kang, Sang-Ahm Lee *
Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanbyeongwon-gil, Songpa-gu, Seoul 138-736, Republic of Korea
A R T I C L E I N F O
Article history:
Received 18 September 2012
Received in revised form 30 November 2012
Accepted 3 December 2012
Keywords:
Levetiracetam
Epilepsy
Efﬁcacy
Drug tolerance
A B S T R A C T
Purpose: The efﬁcacy and safety of the anti-convulsive drug levetiracetam (LEV) has been well
documented but few clinical studies have investigated tolerance to LEV. The aim of this study was to
evaluate the loss of the initial efﬁcacy of LEV in adult patients with refractory partial-onset seizures.
Methods: We enrolled patients with refractory partial epilepsy who were started on add-on LEV
treatment. The efﬁcacy of LEV was evaluated every three months and the seizure frequency was decided
by the average number of monthly seizures. A responder was deﬁned as a patient with a 50% reduction
in seizure frequency from the baseline. Seizure freedom was deﬁned as a seizure-free status from the
beginning of LEV treatment to the evaluation period. Loss of the initial efﬁcacy was deﬁned as a shift from
responder status during the ﬁrst three months of LEV treatment to non-responder status during the
follow-up period.
Results: A total of 95 epilepsy patients were analyzed. During the ﬁrst three months of LEV treatment, 50
(52.6%) of the 95 patients were responders with a 50% seizure reduction. Nine patients (18.0%) showed
a loss of initial efﬁcacy during the second three-month period. In contrast, only two (4.0%) of the non-
responders during the ﬁrst three months became responders during the next three months. However,
this difference did not reach statistical signiﬁcance (P = 0.054). Based on Kaplan–Meier survival
estimates, 49.2% of the patients who initially responded to LEV treatment during the ﬁrst three months
were predicted to lose this response at 42 months. Loss of the initial efﬁcacy of LEV treatment occurred
mostly within 18 months.
Conclusion: This study suggests that the occurrence of tolerance is more common than late gain of
efﬁcacy of treatment although larger prospective studies would have to be carried out to prove this
observation.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Drug tolerance can be deﬁned as a decrease in susceptibility to
the effects of a drug due to its continued administration.1 Several
hypotheses have been suggested to explain the development of
tolerance. The overexpression of multidrug transporters at the
blood–brain barrier is considered to be one factor in this
phenomenon.2 Based on previous data from animal experiments,
many antiepileptic drugs (AEDs) have been demonstrated to be
substrates for multidrug transporters and to show reduced
antiepileptic efﬁcacy due to tolerance development after repeated
administration.1
The efﬁcacy and safety of the anti-convulsant levetiracetam
(LEV), which has a novel structure and unique mechanisms of
action, have been demonstrated in many clinical studies. In
addition, several studies have shown sustained long-term efﬁcacy
of LEV as an add-on therapy.3–8 Pooled data9 in patients with* Corresponding author. Tel.: +82 2 3010 3445; fax: +82 2 474 4691.
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http://dx.doi.org/10.1016/j.seizure.2012.12.002refractory epilepsy treated with LEV during the development
program showed that no tolerance build up to LEV occurs.
However, several animal studies have reported the development of
tolerance to LEV.10–12 A recent study using rats with chronic
epilepsy revealed that LEV treatment led to effective seizure
control but, despite the fact that adequate serum and brain levels
of LEV were maintained, efﬁcacy was lost within a week.12
Incidental evidence also shows that tolerance to LEV can occur in
humans; French et al.3 have reported that the mean proportion of
seizure-free days is higher in the ﬁrst week of LEV treatment than
in subsequent weeks, suggesting tolerance development.
It is important to further investigate whether tolerance to LEV
occurs in human patients. There have been few clinical studies to
date that have addressed this. In most previous studies on the
efﬁcacy of LEV, efﬁcacy was evaluated at a certain time period
without considering those patients who were initial non-
responders but became responders later. Furthermore, no dis-
crimination between lack and loss of efﬁcacy was performed.
Accordingly, the aim of our present study was to evaluate loss of
initial efﬁcacy of LEV in adult patients with refractory partial-onset
seizures.vier Ltd. All rights reserved.
Table 1
Basic patient characteristics.
Total number of patients (n) 95
Gender (male/female) 47 (49.5%)/48 (50.5%)
Age (years), mean  SD 39.1  10.8
Onset age (years), mean  SD 17.3  11.8
Duration of disease (years), mean  SD 21.8  11.2
Risk factors (n)
Encephalitis 17 (17.9%)
Febrile convulsion 13 (13.7%)
Trauma with loss of consciousness 8 (8.4%)
Perinatal injury 8 (5.6%)
Stroke 6 (6.3%)
Previous epilepsy surgery (n) Temporal lobectomy
(5), Lesionectomy (2),
VNS (2), DBS (2)
Number of other AEDs, mean  SD 2.7  1.1
1 concomitant AED (n, %) 9 (9.5%)
2 concomitant AEDs (n, %) 43 (45.3%)
3 concomitant AEDs (n, %) 21 (22.1%)
4 concomitant AEDs (n, %) 22 (23.2%)
Seizure frequency at baseline (n/month) 5.4  21.7
Seizure types (n)
Simple partial 17 (17.9%)
Complex partial 75 (78.9%)
Secondary generalized 81 (85.3%)
Undetermined 3 (3.4%)
Type of epilepsy (n)
Symptomatic 52 (54.7%)
Cryptogenic 43 (45.3%)
DBS: Deep brain stimulation, SD: standard deviation, VNS: vagus nerve stimulation.
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2.1. Subjects
Patients aged at least 18 years with refractory partial epilepsy
who were started on add-on LEV treatment between January 2007
and September 2010 were enrolled in this study. Subjects were
included if they had been receiving one or more concomitant AEDs
at stable doses for at least four weeks prior to selection, if they had
uncontrolled partial seizures with or without secondary generali-
zation at least once a month during the three-month retrospective
baseline period before LEV commencement, if their epilepsy
duration was at least two years from seizure onset, and if they were
followed up for more than six months from LEV treatment
initiation. Subjects were excluded if they had started on other AEDs
simultaneously with LEV or within six months of LEV initiation, if
they discontinued concomitant AED within six months of
commencing LEV therapy, if they had an epilepsy surgery one
year prior to commencing LEV therapy, if they had severe medical
and psychiatric disorders, or if their seizure frequency could not be
counted. All of the patients included in the study had been
regularly monitored by one of four physicians, each a co-author of
this study.
A standardized data form was developed and the data were
obtained retrospectively from individual patient medical records.
Variables included in the database were: age, sex, age at onset,
duration of epilepsy, history of epilepsy surgery, current co-
morbidity, past medical history, epilepsy risk factors, number and
dose of concomitant AEDs, seizure frequency, magnetic resonance
imaging (MRI) results, and electroencephalographic (EEG) ﬁnd-
ings. Epilepsy and seizures were classiﬁed using the International
League Against Epilepsy (ILAE) classiﬁcation.
2.2. LEV treatment
The starting dose was typically 1000 mg per day, divided into
two doses. The LEV dose was increased to 1500 mg or 2000 mg
daily if the patient continued to experience seizures. If seizure
control was not satisfactory and there were no side effects, the
dose was increased to the maximum daily dose (3000 mg per day).
Based on the patient’s and physician’s judgment, the LEV dose
could be reduced or withdrawn.
2.3. Assessment
The efﬁcacy of LEV was evaluated every three months from the
beginning of treatment. The seizure frequency was decided by the
average monthly seizure number during each three-month
interval. A responder was deﬁned as a patient with a 50%
reduction in seizure frequency from the baseline seizure frequency
at three months prior to commencing LEV. Seizure freedom was
deﬁned by a seizure-free status from the beginning of LEV
treatment to the evaluation period. Loss of initial efﬁcacy was
deﬁned as a shift from responder status during the ﬁrst three
months of LEV treatment to non-responder status during the
follow-up period.
2.4. Statistical analysis
Statistical analysis was performed using PASW statistics 18.0
for Windows (SPSS, Chicago, IL). Parametric data are expressed as
the mean  standard deviation (SD). Comparisons between respon-
ders and non-responders groups were analyzed using binary logistic
regression analysis. The difference between patients with loss of
initial efﬁcacy and gain of efﬁcacy in the second three months was
evaluated by Fisher’s exact test. P values of <0.05 were considered tobe statistically signiﬁcant. A Kaplan–Meier survival curve was
generated to analyze the loss of initial efﬁcacy of LEV during the
follow-up period.
3. Results
3.1. Patient characteristics
A total of 95 epilepsy patients were included in the ﬁnal study
cohort (Table 1). The mean seizure frequency of all seizure types
during the baseline period was 3.5  5.3 per month. All patients
were taking AEDs at baseline with 9 (9.5%) taking one AED, 43 (45.3%)
taking two AEDs, 21 (22.1%) taking three AEDs and 22 (23.1%) taking
four or more AEDs. The mean ﬁnal LEV dose was 1373  546 mg/day.
3.2. Initial LEV efﬁcacy
During the ﬁrst three months of LEV treatment, 50 (52.6%) of the
95 patients were responders with a 50% seizure reduction. Age,
age at seizure onset, duration of epilepsy, baseline seizure
frequency, and LEV dosage did not differ between responders
and non-responders. The number of concomitant AEDs was
signiﬁcantly higher in non-responders (3.0  1.1) than responders
(2.4  1.0) (P = 0.004).
3.3. Loss of initial LEV efﬁcacy during the second three-month period
Of the 50 identiﬁed responders during the ﬁrst three months,
the initial efﬁcacy of LEV was lost in 9 (18.0%) cases during the
second three-month period (Fig. 1). Age, age at seizure onset,
duration of epilepsy, baseline seizure frequency, LEV dosage and
number of concomitant AEDs did not differ between the response
maintenance group and those that lost initial LEV efﬁcacy. Of the
45 non-responders recorded during the ﬁrst three months, only
two patients became responders during the second three-month
period. In both of these cases, LEV doses were increased from
1000 mg/day to 2000 mg/day at three or four months from LEV
commencement. Patients with loss of initial efﬁcacy (9/50, 18.0%)
Fig. 1. Loss of initial efﬁcacy of LEV over time.
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gain of efﬁcacy (2/45, 4.4%), but it did not reach statistical
signiﬁcance (P = 0.054).
3.4. Loss of initial LEV efﬁcacy during the long-term follow-up period
The initial efﬁcacy of LEV during the ﬁrst three months (n = 50)
was lost in 21 responders (42.0%) during the entire follow-up
period. Based on Kaplan–Meier survival estimates, 49.2% of
patients who initially responded to LEV treatment during ﬁrst
three months were predicted to lose this response at 42 months
(Fig. 2). The loss of initial LEV efﬁcacy occurred mostly within 18
months.
3.5. Seizure freedom
Seizure freedom was obtained in 29 (30.5%) of 95 patients
during the ﬁrst three months. Seizure freedom was maintained
during the second three-month period and the entire follow-up
period in 16 (16.8%) and 7 (7.4%) patients, respectively (Fig. 1). The
proportion of seizure-free patients decreased markedly and more
rapidly over time so that only 18.9% of patients who becameFig. 2. Estimated response rate to LEV in responders from the ﬁrst three months by
Kaplan–Meier survival analysis.seizure-free during the ﬁrst three months of LEV treatment were
predicted to maintain this response at 18 months by Kaplan–Meier
survival analysis.
3.6. Change in concomitant AEDs
The number and dosage of concomitant AEDs were not changed
within the ﬁrst six months of LEV treatment. Subsequently, one or
more concomitant AEDs were discontinued in 14 cases (34.1%) out
of the 41 patients who remained responders during the ﬁrst six
months. Of these individuals, four patients (28.6%) became non-
responders. Loss of initial LEV efﬁcacy was observed in 8 (29.6%) of
the remaining 27 patients who did not withdraw the concomitant
AEDs. Thus, the proportion that became non-responders did not
differ between patients who did and did not continue taking
concomitant AEDs.
4. Discussion
In this retrospective study we have evaluated the loss of initial
efﬁcacy of LEV in 95 adult patients with refractory partial-onset
seizures. During the ﬁrst 3 months of LEV treatment, 50 patients
(52.6%) were responders with >50% seizure reduction. Only two
non-responders during the ﬁrst 3 months became responders
during the next 3-month period. Initial efﬁcacy of LEV was lost in 9
(18.0%) of 50 initial responders during the second 3-month period.
(Fig. 1) Loss of initial efﬁcacy of LEV treatment was predicted in up
to 49.2% of patients who initially responded to LEV treatment over
42-month follow-up period and occurred mostly within 18 months
of LEV treatment. (Fig. 2)
Our data focusing on loss of initial efﬁcacy of LEV is distinct
from, and cannot be directly compared with, those of previous
studies on the efﬁcacy of LEV due to the fact that most previous
studies used group response analysis.1 Group response analysis
between visits detects a net loss of response but may miss any loss
of initial efﬁcacy in a subgroup if the response improves over time
in initial non-responders. Furthermore, in group response analysis,
no discrimination is made between lack and loss of efﬁcacy. For
these reasons, group response analysis is not a reliable tool with
which to assess the development of tolerance. In this study, we
used individual responder analysis, which can detect an efﬁcacy
shift from responder to non-responder status in individual patients
between visits.1
In our present study, 50 of 95 patients (52.6%) were initial
responders with a 50% seizure reduction during the ﬁrst three
months of LEV treatment. Of 50 initial responders, 9 (18.0%)
showed loss of initial efﬁcacy during the second three-month
period. In contrast, only two (4.4%) non-responders during the ﬁrst
three months became responders during the next three months.
This difference did almost reach statistical signiﬁcance (P = 0.054).
These data suggest that a development of tolerance to LEV occurs
in patients with refractory epilepsy and contrast with the ﬁndings
of a pooled-data study,9 which showed evidence for sustained
efﬁcacy of LEV as add-on therapy in 1325 patients with refractory
epilepsy treated with LEV during the development program. In this
same earlier study, the proportion of responders during the ﬁrst
three months of LEV treatment was 39.2%. Of initial responders,
19.6% became non-responders during the second three months.
However, a change of response in the opposite direction occurred
in 12.0% of non-responders of the ﬁrst three months who became
responders during the second three-month period. Because the
proportion of initial non-responders that became responders was
similar to that of initial responders that became non-responders,
the authors concluded that no tolerance to LEV occurs in this
patient population and that the results could be accounted for by
spontaneous ﬂuctuations in seizure frequency.9
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the pieces of evidence that supports the idea that LEV tolerance
develops in epileptic patients. In our current study, almost one-third
(n = 29, 30.1%) of the total number of patients (95) became seizure-
free during the ﬁrst three months of LEV treatment. The rate of
continued seizure freedom decreased to 16.8% (n = 16) during the
second three-month period and was 7.4% (n = 7) for the entire
follow-up period (Fig. 1). These ﬁndings are consistent with previous
studies. In a US multi-center study4 of the long-term efﬁcacy of LEV
in patients with refractory partial epilepsy, the probability of
remaining seizure-free for the ﬁrst three months of LEV add-on
treatment was 13.4%, which then declined gradually over time. By
four years, the probability of remaining seizure-free from the
beginning of the study was 3.7%. A single-center, prospective one-
year follow-up study13 showed that 15 (19.0%) of 79 patients with
refractory partial epilepsy were seizure-free from the start of LEV
add-on therapy but four patients had a relapse after 1–3 months. The
failure to remain seizure-free during the follow-up period may
suggest the development of tolerance to the drug.
In our present study, Kaplan–Meier analysis predicted that
49.2% of initial responders lost their initial LEV efﬁcacy over the 42-
month follow-up period and that this occurred mostly within 18
months of LEV treatment (Fig. 2). We could not ﬁnd any published
data comparable to our current ﬁndings. The retention rate of
treatment is considered to be a surrogate for the long-term efﬁcacy
and safety of AEDs. Therefore, a decrease in retention rate over
time could be partly explained by a lack or loss of AED efﬁcacy. In a
previous retrospective three-year follow-up study14 in patients
mostly with partial epilepsy treated with LEV as adjunctive
therapy or monotherapy, the retention rate was 75.2% at 12
months of LEV treatment, which then decreased to 53.7% at three
years of LEV treatment. In 79.1% of the patients who discontinued
LEV treatment, the treatment was discontinued due to lack or loss
of efﬁcacy. In another study15 of 1422 patients with epilepsy
exposed to LEV during its developmental program, the retention
rate was estimated to be 60% after one year and 32% after ﬁve years.
Of 486 withdrawals, 46.3% were due to lack or loss of efﬁcacy. In
both of these earlier studies however, no discrimination between
lack and loss of efﬁcacy was made.
The exact mechanism of tolerance to LEV is unknown. LEV
maintains a steady-state level in the serum without metabolism by
CYP450 enzymes.16 Hence, it is not likely that the development of
tolerance to LEV would be due to pharmacokinetic interaction with
concomitant AEDs. However, because LEV was recently reported to
be a substrate for a multidrug transporter in humans,17 tolerance
may be associated with overexpression of multidrug transporters
at the blood–brain barrier, which is considered to be a factor in the
development of drug tolerance.
The present study has some limitations of note. First, several
confounding factors could contribute to a loss of initial efﬁcacy of
AEDs that mimics the development of tolerance to LEV. Reduced
patient compliance, pharmacokinetic changes secondary to
concomitant AEDs, seizure-precipitating factors (e.g., alcohol,
stress, fatigue, and insufﬁcient sleep), and an aggravating
progression of the disease could be incorrectly recognized as
tolerance.1 Second, we did not evaluate the early development of
tolerance to LEV in the three months of LEV treatment. Forexample, French et al.3 reported that the mean proportion of
seizure-free days in patients with refractory epilepsy was higher in
the ﬁrst week of LEV treatment compared with the following
weeks, indicating development of tolerance to LEV in the course of
a few weeks. Third, there were methodological limitations. We
used individual responder analysis to evaluate loss of initial
efﬁcacy,1 but this method also cannot exclude ‘the effect of
regression to the mean’.18 In addition, the group sizes in this study
were not big enough for showing a signiﬁcant effect. Sample size
was estimated using power-based sample size calculations. A
sample size of at least 77 patients in both groups (responders/non-
responders) would have been needed to achieve a signiﬁcance
level of <0.05 at a power of 80%.
In conclusion, our study suggests that the occurrence of
tolerance is more common than late gain of efﬁcacy of treatment
although larger prospective studies would have to be carried out to
prove this observation.
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